Eculizumab

1. Helps to stabilize or increase the haemoglobin levels in most patients during the maintenance therapy.
2. Results in a low need for blood transfusion during treatment and a low rate of breakthrough haemolysis.
3. Improves the patient’s quality of life and reduces fatigue.

⇒Therapeutic Indications:

Eculizumab is indicated for the treatment of patients with:

•Paroxysmal nocturnal haemoglobinuria (PNH).

•Atypical haemolytic uremic syndrome (aHUS)

⇒Formulation:

Eculizumab is supplied as a concentrate for solution for infusion as a 300 mg vial.